BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gkountakos A, Delfino P, Lawlor RT, Scarpa A, Corbo V, Bria E. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients. Ther Adv Med Oncol 2021;13:17588359211006947. [PMID: 34104224 DOI: 10.1177/17588359211006947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Li H, Guo M, Zhang J, Zhang G, Sun N, Feng Y, Cui W, Xu F. FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma. Immunotherapy 2023;15:235-52. [PMID: 36695131 DOI: 10.2217/imt-2022-0195] [Reference Citation Analysis]
2 Wang M, Zhu L, Yang X, Li J, Liu Y, Tang Y. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer. Front Pharmacol 2023;14:1132158. [PMID: 36874015 DOI: 10.3389/fphar.2023.1132158] [Reference Citation Analysis]
3 Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers 2022;14:4562. [DOI: 10.3390/cancers14194562] [Reference Citation Analysis]
4 Hu Z, Xue C, Zheng J, Lu X, Li J, Dong H, Yu Y, Zhang X, Tan K, Cui H, Jiang F. Hyper-Methylated Hub Genes of T-Cell Receptor Signaling Predict a Poor Clinical Outcome in Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/5426887] [Reference Citation Analysis]